Last10K.com

Adverum Biotechnologies, Inc. (ADVM) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Adverum Biotechnologies, Inc.

HISTORY TOOLS
CIK: 1501756 Ticker: ADVM
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Feb. 28, 2019
Jun. 30, 2018
Document And Entity Information [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2018  
Document Fiscal Year Focus2018  
Document Fiscal Period FocusFY  
Trading SymbolADVM  
Entity Registrant NameAdverum Biotechnologies, Inc.  
Entity Central Index Key0001501756  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerNo  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Filer CategoryAccelerated Filer  
Entity Emerging Growth Companytrue  
Entity Ex Transition Periodtrue  
Entity Small Businesstrue  
Entity Shell Companyfalse  
Entity Common Stock, Shares Outstanding 63,201,009 
Entity Public Float  $ 294.8

View differences made from one year to another to evaluate Adverum Biotechnologies, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adverum Biotechnologies, Inc..

Continue

Assess how Adverum Biotechnologies, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adverum Biotechnologies, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Product
Cash Flow
Shares
Income
Other
Inside Adverum Biotechnologies, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (Parenthetical)
401(K) Savings Plan
401(K) Savings Plan - Additional Information (Detail)
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Tables)
Accrued Expenses And Other Current Liabilities - Schedule Of Accrued Expenses And Other Current Liabilities (Detail)
Cash Equivalents And Short-Term Investments
Cash Equivalents And Short-Term Investments (Tables)
Cash Equivalents And Short-Term Investments - Additional Information (Detail)
Cash Equivalents And Short-Term Investments - Summary Of Cash Equivalents And Short-Term Investments (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Schedule Of Future Minimum Commitments Under Facility Operating Leases (Detail)
Common Stock Warrants
Common Stock Warrants - Additional Information (Detail)
Description Of The Business
Description Of The Business - Additional Information (Detail)
Fair Value Measurements And Fair Value Of Financial Instruments
Fair Value Measurements And Fair Value Of Financial Instruments (Tables)
Fair Value Measurements And Fair Value Of Financial Instruments - Additional Information (Detail)
Fair Value Measurements And Fair Value Of Financial Instruments - Financial Assets And Liabilities Measured And Recognized At Fair Value On Recurring Basis (Detail)
Financing Arrangements
Financing Arrangements (Tables)
Financing Arrangements - Additional Information (Detail)
Financing Arrangements - Summary Of Tap Financing Activity (Detail)
Impairment Evaluation For Goodwill And Intangible Assets
Impairment Evaluation For Goodwill And Intangible Assets - Additional Information (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Components Of Loss Before Income Taxes (Detail)
Income Taxes - Schedule Of Deferred Tax Assets (Detail)
Income Taxes - Schedule Of Reconciliation Of Income Tax Expense Computed Statutory Federal Income Tax And Financial Statements (Detail)
Income Taxes - Schedule Of Unrecognized Tax Benefits (Detail)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Schedule Of Antidilutive Common Stock Equivalents Excluded From Calculation Of Diluted Net Loss Per Share (Detail)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Additional Information (Detail)
Property And Equipment, Net - Schedule Of Property And Equipment, Net (Detail)
Selected Quarterly Financial Information
Selected Quarterly Financial Information (Tables)
Selected Quarterly Financial Information - Schedule Of Quarterly Consolidated Results Of Operations (Detail)
Selected Quarterly Financial Information - Schedule Of Quarterly Consolidated Results Of Operations (Parenthetical) (Detail)
Significant Agreements
Significant Agreements - Additional Information (Detail)
Stock Plans
Stock Plans (Tables)
Stock Plans - Additional Information (Detail)
Stock Plans - Schedule Of Employees Stock Purchase Plan Valuation Assumptions (Detail)
Stock Plans - Stock-Based Compensation Expense (Detail)
Stock Plans - Summary Of Restricted Stock Units Activity (Detail)
Stock Plans - Summary Of Stock Options Activity (Detail)
Stock Plans - Summary Of Stock Options Activity (Parenthetical) (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Ticker: ADVM
CIK: 1501756
Form Type: 10-K Annual Report
Accession Number: 0001564590-19-006536
Submitted to the SEC: Wed Mar 06 2019 12:31:25 PM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Monday, December 31, 2018
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/advm/0001564590-19-006536.htm